(Q36996294)

17 August 2017

1 reference

title

Thiazolidinediones as anti-inflammatory and anti-atherogenic agents (English)

1 reference

17 August 2017

1 reference

1

1 reference

17 August 2017

publication date

1 January 2008

1 reference

Diabetes - Metabolism: Research and Reviews

17 August 2017

published in

1 reference

17 August 2017

volume

24

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

14-26

1 reference

Oxidative stress and diabetes-associated complications

17 August 2017

cites work

1 reference

The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications

21 January 2018

1 reference

Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats

21 January 2018

1 reference

Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study

21 January 2018

1 reference

Duration of diabetes and carotid wall thickness. The Insulin Resistance Atherosclerosis Study (IRAS).

21 January 2018

1 reference

Mediators produced by the endothelial cell

21 January 2018

1 reference

Covered stent septal ablation for hypertrophic obstruction cardiomyopathy

21 January 2018

1 reference

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients

21 January 2018

1 reference

C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

21 January 2018

1 reference

The pathobiology of diabetic complications: a unifying mechanism

21 January 2018

1 reference

7 January 2021

Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention

1 reference

7 January 2021

Improving macrovascular outcomes in type 2 diabetes: Outcome studies in cardiovascular risk and metabolic control

1 reference

7 January 2021

Oxidative stress as the leading cause of acute myocardial infarction in diabetics

1 reference

7 January 2021

Peroxisome proliferator-activated receptors in inflammation control

1 reference

7 January 2021

1 reference

7 January 2021

The mechanisms of action of PPARs

1 reference

7 January 2021

Peroxisome proliferator-activated receptor gamma and metabolic disease.

1 reference

7 January 2021

Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients

1 reference

7 January 2021

Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes

1 reference

7 January 2021

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

1 reference

7 January 2021

1 reference

7 January 2021

PPARgamma and atherosclerosis

1 reference

7 January 2021

Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators

1 reference

7 January 2021

Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes

1 reference

7 January 2021

Cellular and molecular mechanisms of endothelial cell dysfunction

1 reference

7 January 2021

Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients

1 reference

7 January 2021

Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation

1 reference

7 January 2021

Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited

1 reference

7 January 2021

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

1 reference

7 January 2021

PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice

1 reference

7 January 2021

Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size

1 reference

7 January 2021

Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury

1 reference

7 January 2021

Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation

1 reference

7 January 2021

Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat.

1 reference

7 January 2021

Improvement of aortic wall distensibility and reduction of oxidative stress by pioglitazone in pre-diabetic stage of Otsuka Long-Evans Tokushima fatty rats

1 reference

7 January 2021

PPARγ activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes

1 reference

7 January 2021

Altered Gene Expression Related to Glomerulogenesis and Podocyte Structure in Early Diabetic Nephropathy of db/db Mice and Its Restoration by Pioglitazone

1 reference

7 January 2021

Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes

1 reference

7 January 2021

Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors

1 reference

7 January 2021

Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes.

1 reference

7 January 2021

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

1 reference

7 January 2021

Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes

1 reference

7 January 2021

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

1 reference

7 January 2021

Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria

1 reference

7 January 2021

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

1 reference

7 January 2021

Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization

1 reference

7 January 2021

A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome

1 reference

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

7 January 2021

Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic Syndrome

1 reference

7 January 2021

Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes

1 reference

7 January 2021

Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice

1 reference

7 January 2021

Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics

1 reference

7 January 2021

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

1 reference

7 January 2021

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

7 January 2021

Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study

1 reference

7 January 2021

Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers

1 reference

7 January 2021

Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells

1 reference

7 January 2021

Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

1 reference

7 January 2021

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

1 reference

7 January 2021

The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation

1 reference

7 January 2021

Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study

1 reference

7 January 2021

The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment

1 reference

7 January 2021

Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products

1 reference

7 January 2021

Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels

1 reference

7 January 2021

Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation

1 reference

7 January 2021

Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: a randomized study

1 reference

7 January 2021

Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease

1 reference

7 January 2021

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus

1 reference

7 January 2021

Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome

1 reference

7 January 2021

Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome

1 reference

7 January 2021

Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones

1 reference

7 January 2021

Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production

1 reference

7 January 2021

New insight into the pathophysiology of lipid abnormalities in type 2 diabetes

1 reference

7 January 2021

Antiinflammatory properties of HDL.

1 reference

7 January 2021

Common carotid artery intima-media thickness and brain infarction : the Etude du Profil Génétique de l'Infarctus Cérébral (GENIC) case-control study. The GENIC Investigators

1 reference

7 January 2021

Impaired glucose tolerance, Type II diabetes mellitus and carotid atherosclerosis: prospective results from the Bruneck Study

1 reference

7 January 2021

Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients

1 reference

7 January 2021

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

1 reference

7 January 2021

Atherosclerosis — An Inflammatory Disease

1 reference

7 January 2021

Platelets in inflammation and atherogenesis.

1 reference

7 January 2021

Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus

1 reference

7 January 2021

Platelet dysfunction in type 2 diabetes

1 reference

7 January 2021

Decreased Sensitivity of Platelets to Prostacyclin in Patients with Diabetes Mellitus

1 reference

7 January 2021

Troglitazone has a reducing effect on thromboxane production

1 reference

7 January 2021

Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism.

1 reference

7 January 2021

Platelets as a novel target for PPARgamma ligands : implications for inflammation, diabetes, and cardiovascular disease

1 reference

7 January 2021

Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1

1 reference

7 January 2021

Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease

1 reference

7 January 2021

Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatab

1 reference

7 January 2021

Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases

1 reference

7 January 2021

Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries

1 reference

7 January 2021

Coagulation and atherothrombotic disease

1 reference

7 January 2021

Fibrinogen and fibrin clot structure in diabetes

1 reference

7 January 2021

The influence of type 2 diabetes on fibrin structure and function

1 reference

7 January 2021

Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications

1 reference

7 January 2021

Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions.

1 reference

7 January 2021

Endothelial dysfunction, inflammation and diabetes

1 reference

7 January 2021

Detection and localization of tumor necrosis factor in human atheroma

1 reference

7 January 2021

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

1 reference

7 January 2021

Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart

1 reference

7 January 2021

TNF-induced cardiomyopathy

1 reference

7 January 2021

Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction

1 reference

7 January 2021

The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase

1 reference

7 January 2021

Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome

1 reference

7 January 2021

The acute phase response

1 reference

7 January 2021

Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome

1 reference

7 January 2021

Adiponectin: A novel adipokine linking adipocytes and vascular function

1 reference

7 January 2021

Plasma adiponectin levels and risk of myocardial infarction in men.

1 reference

7 January 2021

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity

1 reference

7 January 2021

Serum adiponectin and leptin levels in patients with lipodystrophies

1 reference

7 January 2021

Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression

1 reference

7 January 2021

Adiponectin and development of type 2 diabetes in the Pima Indian population

1 reference

7 January 2021

Adiponectin and protection against type 2 diabetes mellitus

1 reference

7 January 2021

C-reactive protein fifty years on

1 reference

7 January 2021

Acute-phase proteins and other systemic responses to inflammation

1 reference

7 January 2021

C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction

1 reference

7 January 2021

C-reactive protein: risk marker or mediator in atherothrombosis?

1 reference

7 January 2021

1 reference

7 January 2021

Interleukin-6 and cardiovascular diseases

1 reference

7 January 2021

Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall

1 reference

7 January 2021

Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly

1 reference

7 January 2021

NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X

1 reference

7 January 2021

Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina

1 reference

7 January 2021

Cytokine milieu tends toward inflammation in type 2 diabetes

1 reference

7 January 2021

Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes

1 reference

7 January 2021

Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes

1 reference

7 January 2021

High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes.

1 reference

7 January 2021

Plasma MMP-9 - a marker of carotid plaque instability

1 reference

7 January 2021

Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis

1 reference

7 January 2021

Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes

1 reference

7 January 2021

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study

1 reference

7 January 2021

Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)

1 reference

7 January 2021

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

7 January 2021

Rosiglitazone and cardiovascular risk

1 reference

7 January 2021

The DREAM trial – Authors' reply

1 reference

7 January 2021

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

7 January 2021

A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.790

1 reference

17 August 2017

1 reference